Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.770
+0.005 (0.65%)
At close: May 1, 2024, 4:00 PM
0.750
-0.020 (-2.60%)
Pre-market: May 2, 2024, 6:45 AM EDT

Aligos Therapeutics Revenue

In the year 2023, Aligos Therapeutics had annual revenue of $15.53M with 11.66% growth. Revenue in the quarter ending December 31, 2023 was $2.68M, a -24.20% decrease year-over-year.

Revenue (ttm)
$15.53M
Revenue Growth
+11.66%
P/S Ratio
3.60
Revenue / Employee
$235,288
Employees
66
Market Cap
55.88M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202315.53M1.62M11.66%
Dec 31, 202213.91M9.55M219.04%
Dec 31, 20214.36M--
Dec 31, 20200--
Dec 31, 20190--
Dec 31, 20180--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
NeueHealth 1.16B
Eagle Pharmaceuticals 257.55M
Bionano Genomics 36.12M
Prenetics Global 21.74M
HCW Biologics 560.36K
Revenue Rankings